Drug approvals

Pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
November 09, 2020 - 5:48 pm
Pfizer's surprising news that its COVID-19 vaccine might offer more protection than anticipated — an announcement right after a fraught U.S. presidential election campaign — is raising questions about exactly how the different shots will make it to market. Pfizer Inc. and the maker of the other...
Read More
In this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer’s disease research in a laboratory at the drugmaker’s headquarters in Cambridge, Mass. On Friday, Nov. 6, 2020, a panel of outside experts will meet to advise the Food and Drug Administration on the drug, called aducanumab from Biogen Inc. and Japan’s Eisai Co. The drug does not cure or reverse Alzheimer’s; the claim is that it modestly slows the rate of decline. (David A. White/Biogen via AP)
November 06, 2020 - 2:50 pm
WASHINGTON (AP) — Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease. The panel of outside experts for the Food and Drug Administration agreed that a...
Read More
FILE - In this Wednesday, June 24, 2020 file photo, a volunteer receives an injection at the Chris Hani Baragwanath hospital in Soweto, Johannesburg, as part of Africa's first participation in a COVID-19 vaccine trial developed at the University of Oxford in Britain in conjunction with the pharmaceutical company AstraZeneca. On Friday, Oct. 23, 2020, AstraZeneca Inc. announced that the Food and Drug Administration is letting it resume testing of its COVID-19 vaccine candidate in the U.S. (Siphiwe Sibeko/Pool via AP)
Associated Press
November 05, 2020 - 1:51 pm
LONDON (AP) — AstraZeneca hopes to show its COVID-19 vaccine is effective by the end of this year and is ramping up manufacturing so it can supply hundreds of millions of doses starting in January, Chief Executive Pascal Soriot said Thursday. The Anglo-Swedish drugmaker is working with the...
Read More
FILE - In this July 17, 2020 file photo, a senior citizen holds the hand of a care coordinator at a Health facility in Miami. Federal health officials on Friday unveiled a plan to get approved coronavirus vaccines to nursing home residents free of cost, with the aid of two national pharmacy chains. No vaccine has yet been approved by the Food and Drug Administration, and the distribution program is contingent on that happening first. (AP Photo/Wilfredo Lee)
Associated Press
October 16, 2020 - 9:24 am
WASHINGTON (AP) — Federal health officials on Friday unveiled a plan to get approved coronavirus vaccines to nursing home residents free of cost, with the aid of two national pharmacy chains. No vaccine has yet been approved by the Food and Drug Administration, and the distribution program is...
Read More
This image provided by Regeneron on Wednesday, Oct. 14, 2020, shows a vial of the company's Inmazeb medication. On Wednesday, the U.S. Food and Drug Administration said it has approved the drug for treating Ebola in both adults and children. (Regeneron via AP)
October 14, 2020 - 5:44 pm
U.S. regulators Wednesday approved the first drug for the treatment of Ebola. The Food and Drug Administration OK'd the drug developed by Regeneron Pharmaceuticals for treating adults and children with the Zaire Ebola virus strain, the most deadly of six known types. It typically kills 60% to 90%...
Read More
FILE - In this Tuesday, May 13, 2014 file photo, AstraZeneca CEO Pascal Soriot leaves the British Parliament's Business Innovation and Skills Committee after a hearing in central London. Two firms developing COVID-19 vaccines say pharmaceutical companies are trying to give the public as much information as possible about their testing regimes as drugmakers and public health officials seek to boost confidence that any approved vaccine will be safe. AstraZeneca CEO Pascal Soriot and Paul Stoffels, chief scientific officer of Johnson & Johnson, said Thursday Sept. 24, 2020, that they recognize the coronavirus emergency demands increased transparency from vaccine developers to ensure the public has faith in the end product. (AP Photo/Lefteris Pitarakis, File)
September 24, 2020 - 4:32 am
LONDON (AP) — Two firms developing COVID-19 vaccines say pharmaceutical companies are trying to give the public as much information as possible about their testing regimes as drugmakers and public health officials seek to boost confidence that any approved vaccine will be safe. AstraZeneca CEO...
Read More
FILE - In this Monday, July 27, 2020 file photo, a nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. On Tuesday, Sept. 8, 2020, the top executives of nine drugmakers likely to produce the first vaccines against the new coronavirus said that they will stick to the highest ethical and scientific standards in testing and manufacturing and will make the well-being of those getting vaccinated their top priority. (AP Photo/Hans Pennink)
September 08, 2020 - 9:46 am
The top executives of nine drugmakers likely to produce the first vaccines against the new coronavirus signed an unprecedented pledge meant to boost public confidence in any approved vaccines. The companies said Tuesday that they will stick to the highest ethical and scientific standards in testing...
Read More
FILE - In this July 27, 2020, file photo, Nurse Kathe Olmstead, right, gives volunteer Melissa Harting, of Harpersville, N.Y., an injection as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. A letter from federal health officials instructing states to be ready to begin distributing a vaccine by Nov. 1 — two days before the election — has met, not with exhilaration, but with suspicion among public health experts and others. (AP Photo/Hans Pennink, File)
September 03, 2020 - 1:35 pm
Could the U.S. really see a coronavirus vaccine before Election Day? A letter from federal health officials instructing states to be ready to begin distributing a vaccine by Nov. 1 — two days before the election — has been met, not with exhilaration, but with suspicion among some public health...
Read More
FILE - This Aug. 2, 2018, file photo shows the U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. Investors are driving shares of drug developer BioMarin down by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients. The FDA's rejection late Tuesday, Aug. 18, 2020, means BioMarin will have to complete an ongoing late-stage patient study. (AP Photo/Jacquelyn Martin, File)
August 19, 2020 - 12:07 pm
FAIRLESS HILLS, PA (AP) — Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime treatment. The U.S...
Read More
President Donald Trump speaks at a news conference in the James Brady Press Briefing Room at the White House, Thursday, Aug. 13, 2020, in Washington. (AP Photo/Andrew Harnik)
August 18, 2020 - 1:47 pm
ISLAMABAD — Pakistan’s drug regulatory agency has approved final-phase testing of a Chinese-made vaccine against coronavirus in this Islamic nation where the new virus has caused 617 deaths since February. In Monday’s statement, the state-run National Institute of Health said the approval to carry...
Read More

Pages